ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Efficacy and safety data in elderly patients (pts) with metastatic renal cell carcinoma (mRCC) included in the nivolumab expanded access program (EAP) in Italy
Annals of Oncology
◽
10.1093/annonc/mdx371.051
◽
2017
◽
Vol 28
◽
pp. v318
Author(s):
R. Sabbatini
◽
L. Galli
◽
S. Pignata
◽
G. Lo Re
◽
F. Valcamonico
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Elderly Patients
◽
Cell Carcinoma
◽
Metastatic Renal Cell Carcinoma
◽
Renal Cell
◽
Safety Data
◽
Efficacy And Safety
◽
Expanded Access
◽
Expanded Access Program
◽
Access Program
Download Full-text
Related Documents
Cited By
References
Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy
PLoS ONE
◽
10.1371/journal.pone.0199642
◽
2018
◽
Vol 13
(7)
◽
pp. e0199642
◽
Cited By ~ 10
Author(s):
Maria Giuseppa Vitale
◽
Sarah Scagliarini
◽
Luca Galli
◽
Sandro Pignata
◽
Giovanni Lo Re
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Elderly Patients
◽
Cell Carcinoma
◽
Metastatic Renal Cell Carcinoma
◽
Renal Cell
◽
Safety Data
◽
Efficacy And Safety
◽
Expanded Access
◽
Expanded Access Program
◽
Access Program
Download Full-text
696P Is it possible to improve the prognostic ability of the IMDC score? Validation of the Meet-URO score in metastatic renal cell carcinoma (mRCC) patients (pts) receiving first-line nivolumab plus ipilimumab in the Italian Expanded Access Program (EAP)
Annals of Oncology
◽
10.1016/j.annonc.2021.08.092
◽
2021
◽
Vol 32
◽
pp. S709
Author(s):
S.E. Rebuzzi
◽
A. Signori
◽
M. Maruzzo
◽
G. Tortora
◽
L. Galli
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Metastatic Renal Cell Carcinoma
◽
Renal Cell
◽
First Line
◽
Expanded Access
◽
Expanded Access Program
◽
Access Program
Download Full-text
7148 POSTER Hyperglycemia and Hypercholesterolemia and Associated Outcomes of Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus in the Expanded-access Program REACT
European Journal of Cancer
◽
10.1016/s0959-8049(11)72063-9
◽
2011
◽
Vol 47
◽
pp. S519
◽
Cited By ~ 1
Author(s):
P. Bono
◽
D. Kim
◽
A. Panneerselvam
◽
V. Grünwald
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Metastatic Renal Cell Carcinoma
◽
Renal Cell
◽
Expanded Access
◽
Expanded Access Program
◽
Access Program
Download Full-text
REACT expanded-access program in patients with metastatic renal cell carcinoma: real-world data from a European subanalysis
Future Oncology
◽
10.2217/fon.15.241
◽
2015
◽
Vol 11
(21)
◽
pp. 2893-2903
◽
Cited By ~ 2
Author(s):
Sergio Bracarda
◽
Sylvie Rottey
◽
Amit Bahl
◽
Christian Eichelberg
◽
Begoña Mellado
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Metastatic Renal Cell Carcinoma
◽
Real World
◽
Renal Cell
◽
Real World Data
◽
World Data
◽
Expanded Access
◽
Expanded Access Program
◽
Access Program
Download Full-text
Negative prognostic factors and resulting clinical outcome in patients (pts) with metastatic renal cell carcinoma (mRCC) included in the Italian nivolumab expanded access program (EAP)
Annals of Oncology
◽
10.1093/annonc/mdx371.041
◽
2017
◽
Vol 28
◽
pp. v314
Author(s):
S. Bracarda
◽
L. Galli
◽
M. Maruzzo
◽
G. Lo Re
◽
S. Buti
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Prognostic Factors
◽
Clinical Outcome
◽
Cell Carcinoma
◽
Metastatic Renal Cell Carcinoma
◽
Renal Cell
◽
Expanded Access
◽
Expanded Access Program
◽
Access Program
Download Full-text
Cabozantinib in metastatic renal cell carcinoma (mRCC): Data from UK expanded access program (EAP)
Annals of Oncology
◽
10.1093/annonc/mdy283.102
◽
2018
◽
Vol 29
◽
pp. viii317
Author(s):
A. Gomez de Liano Lista
◽
B. Venugopal
◽
K. Fife
◽
S. Symeonides
◽
N.S. Vasudev
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Metastatic Renal Cell Carcinoma
◽
Renal Cell
◽
Expanded Access
◽
Expanded Access Program
◽
Access Program
Download Full-text
Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program
Future Oncology
◽
10.2217/fon-2017-0570
◽
2018
◽
Vol 14
(14)
◽
pp. 1347-1354
◽
Cited By ~ 2
Author(s):
Sergio Bracarda
◽
Luca Galli
◽
Marco Maruzzo
◽
Giovanni Lo Re
◽
Sebastiano Buti
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Prognostic Factors
◽
Clinical Outcome
◽
Cell Carcinoma
◽
Metastatic Renal Cell Carcinoma
◽
Renal Cell
◽
Expanded Access
◽
Expanded Access Program
◽
Access Program
Download Full-text
Are adverse events (AEs) predictive of nivolumab activity? Data from the Italian expanded access program in metastatic renal cell carcinoma (mRCC)
Annals of Oncology
◽
10.1093/annonc/mdy283.094
◽
2018
◽
Vol 29
◽
pp. viii314
Author(s):
E. Verzoni
◽
G. Cartenì
◽
E. Cortesi
◽
F. Roila
◽
M.G. Vitale
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Adverse Events
◽
Cell Carcinoma
◽
Metastatic Renal Cell Carcinoma
◽
Renal Cell
◽
Activity Data
◽
Expanded Access
◽
Expanded Access Program
◽
Access Program
Download Full-text
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
Journal for ImmunoTherapy of Cancer
◽
10.1186/s40425-019-0579-z
◽
2019
◽
Vol 7
(1)
◽
Cited By ~ 28
Author(s):
Elena Verzoni
◽
◽
Giacomo Cartenì
◽
Enrico Cortesi
◽
Diana Giannarelli
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Adverse Events
◽
Cell Carcinoma
◽
Metastatic Renal Cell Carcinoma
◽
Real World
◽
Renal Cell
◽
Efficacy And Safety
◽
Expanded Access Program
◽
Previously Treated
◽
Access Program
Download Full-text
SAFETY AND EFFICACY OF SUNITINIB IN METASTATIC RENAL CELL CARCINOMA (mRCC): PRELIMINARY ASSESSMENT OF AN ITALIAN EXPANDED-ACCESS PROGRAM (EAP) WITH SUBPOPULATION ANALYSIS
The Journal of Urology
◽
10.1016/s0022-5347(08)61225-2
◽
2008
◽
Vol 179
(4S)
◽
pp. 418-418
Author(s):
Cora N Sternberg
◽
Camillo Porta
◽
Sergio Bracarda
◽
Giacomo Carteni
◽
Giovanni Lo Re
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Metastatic Renal Cell Carcinoma
◽
Renal Cell
◽
Preliminary Assessment
◽
Safety And Efficacy
◽
Expanded Access
◽
Expanded Access Program
◽
Access Program
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close